Role of Additional Novel Therapies in Myeloproliferative Neoplasms

Hematology/Oncology Clinics of North America

Volumn 26, Issue 5, 2012, Pages 959-980

  Fiskus, Warren ^a   Ganguly, Siddhartha ^a   Kambhampati, Suman ^a   Bhalla, Kapil N ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

HDAC inhibitor; Hsp90 inhibitors; JAK2 V617F; MEK inhibitor; Myeloproliferative neoplasms; PI3K AKT inhibitor

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; 5 AZA 2' DEOXYCYTIDINE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AZD 1208; BC 2059; BMS 911543; EVEROLIMUS; GIVINOSTAT; HYDROXYUREA; JANUS KINASE 2; JANUS KINASE INHIBITOR; LESTAURTINIB; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PANOBINOSTAT; PF 04449913; PU H71; ROMIDEPSIN; RUXOLITINIB; SELUMETINIB; SGI 1776; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; TANESPIMYCIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE; VORINOSTAT;

ALLOGENEIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CELL CYCLE; ENZYME ACTIVITY; EPIGENETICS; GENE MUTATION; HUMAN; LEUKEMIA; LOW DRUG DOSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

HUMANS; JANUS KINASES; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; PYRAZOLES; SIGNAL TRANSDUCTION;

EID: 84866633871     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.07.001     Document Type: Review

References (137)

1. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
2. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
3. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
4. Levine R.L., Gilliland D.G. Myeloproliferative disorders. Blood 2008, 112:2190-2198.
5. Levine R.L., Pardanani A., Tefferi A., et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007, 7:673-683.
6. Baker S.J., Rane S.G., Reddy E.P. Hematopoietic cytokine receptor signaling. Oncogene 2007, 26:6724-6737.
7. Oku S., Takenaka K., Kuriyama T., et al. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation. Br J Haematol 2010, 150:334-344.
8. Ungureanu D., Wu J., Pekkala T., et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 2011, 18:971-976.
9. Sanz A., Ungureanu D., Pekkala T., et al. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation. PLoS One 2011, 6:e18522.
10. Friedbichler K., Kerenyi M.A., Kovacic B., et al. Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood 2010, 116:1548-1558.
11. Dawson M.A., Bannister A.J., Gottgens B., et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009, 461:819-822.
12. He J., Zhang Y. Janus kinase 2: an epigenetic 'writer' that activates leukemogenic genes. J Mol Cell Biol 2010, 2:231-233.
13. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356:459-468.
14. Pardanani A.D., Levine R.L., Lasho T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472-3476.
15. Levine R.L., Wernig G. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2006, 1:233-239.
16. Koppikar P., Abdel-Wahab O., Hedvat C., et al. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood 2010, 115:2919-2927.
17. Makishima H., Cazzolli H., Szpurka H., et al. Mutations of the e3 ubiquitin ligase cbl family members constitute a novel pathogenic lesion in myeloid malignancies. J Clin Oncol 2009, 27:6109-6116.
18. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010, 24:1128-1138.
19. Delhommeau F., Jeziorowska D., Marzac C., et al. Molecular aspects of myeloproliferative neoplasms. Int J Hematol 2010, 91:165-173.
20. Vainchenker W., Delhommeau F., Constantinescu S.N., et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011, 118:1723-1735.
21. Pardanani A., Lasho T., Finke C., et al. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia 2010, 24:1713-1718.
22. Oh S.T., Simonds E.F., Jones C., et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010, 116:988-992.
23. Abdel-Wahab O. Genetics of the myeloproliferative neoplasms. Curr Opin Hematol 2011, 18:117-123.
24. Quintas-Cardama A., Kantarjian H., Cortes J., et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011, 10:127-140.
25. Chappell W.H., Steelman L.S., Long J.M., et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011, 2:135-164.
26. Steelman L.S., Franklin R.A., Abrams S.L., et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011, 25:1080-1094.
27. Chung E., Hsu C.L., Kondo M. Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder. PLoS One 2011, 6:e28350.
28. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9:550-562.
29. Wernig G., Gonneville J.R., Crowley B.J., et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 2008, 111:3751-3759.
30. Shah N., Pang B., Yeoh K.G., et al. Potential roles for the PIM1 kinase in human cancer- a molecular and therapeutic appraisal. Eur J Cancer 2008, 44:2144-2151.
31. Abdel-Wahab O., Pardanani A., Patel J., et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011, 25:1200-1202.
32. Carbuccia N., Murati A., Trouplin V., et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009, 23:2183-2186.
33. Tefferi A., Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011, 29:573-582.
34. Chase A., Cross N.C. Aberrations of EZH2 in cancer. Clin Cancer Res 2011, 17:2613-2618.
35. Martin-Perez D., Piris M.A., Sanchez-Beato M. Polycomb proteins in hematologic malignancies. Blood 2010, 116:5465-5475.
36. Ernst T., Chase A.J., Score J., et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010, 42:722-726.
37. Guglielmelli P., Biamonte F., Score J., et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011, 118:5227-5234.
38. Ricci C., Spinelli O., Salmoiraghi S., et al. ASXL1 mutations in primary and secondary myelofibrosis. Br J Haematol 2012, 156:404-407.
39. Levine RL. Mutations in epigenetic modifiers in MPN and MDS pathogenesis. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 March 31-April 4. Chicago (IL), Philadelphia: AACR; 2012. Abstract NC18.
40. Guglielmelli P., Biamonte F., Score J., et al. Prognostic impact of EZH2 and ASXL1 mutation in myelofibrosis. ASH Annual Meeting Abstracts 2011, 118:2811.
41. Stein B.L., Williams D.M., O'Keefe C., et al. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes. Haematologica 2011, 96:1462-1469.
42. Ko M., Huang Y., Jankowska A.M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
43. Tefferi A., Pardanani A., Lim K.H., et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009, 23:905-911.
44. Martinez-Aviles L., Besses C., Alvarez-Larran A., et al. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms. Ann Hematol 2012, 91(4):533-541.
45. Gross S., Cairns R.A., Minden M.D., et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010, 207:339-344.
46. Ward P.S., Patel J., Wise D.R., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-234.
47. Figueroa M.E., Abdel-Wahab O., Lu C., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.
48. Xu W., Yang H., Liu Y., et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
49. Chowdhury R., Yeoh K.K., Tian Y.M., et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 2011, 12:463-469.
50. Lu C., Ward P.S., Kapoor G.S., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478.
51. Sulai N., Jimma T., Lasho T.L., et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. ASH Annual Meeting Abstracts 2011, 118:1751.
52. Tefferi A., Jimma T., Sulai N.H., et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 2012, 26:475-480.
53. Stegelmann F., Bullinger L., Schlenk R.F., et al. DNMT3A mutations in myeloproliferative neoplasms. Leukemia 2011, 25:1217-1219.
54. Challen G.A., Sun D., Jeong M., et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 2012, 44:23-31.
55. Brecqueville M., Rey J., Bertucci F., et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer 2012, 51(8):743-755.
56. Abdel-Wahab O., Pardanani A., Rampal R., et al. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 2011, 25:1219-1220.
57. Walter M.J., Ding L., Shen D., et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011, 25:1153-1158.
58. Metzeler K.H., Walker A., Geyer S., et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 2012, 26(5):1106-1107.
59. Passamonti F., Maffioli M., Caramazza D. New generation small-molecule inhibitors in myeloproliferative neoplasms. Curr Opin Hematol 2012, 19:117-123.
60. Verstovsek S., Kantarjian H., Mesa R.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010, 363:1117-1127.
61. Mascarenhas J., Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res 2012, 18(11):3008-3014.
62. Tefferi A. JAK inhibitors for myeloproliferative neoplasms; clarifying facts from myths. Blood 2012, 119:2721-2730.
63. Pardanani A., Gotlib J.R., Jamieson C., et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011, 29:789-796.
64. Tefferi A. Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms. N Engl J Med 2012, 366:844-846.
65. Deshpande A., Reddy M.M., Schade G., et al. Kinase domain mutations in JAK2V617F confer resistance to the novel JAK2 inhibitor ruxolitinib. ASH Annual Meeting Abstracts 2011, 118:125.
66. Kalota A., Jeschke G.R., Carroll M., et al. Intrinsic resistance to JAK2 inhibition in myelofibrosis. ASH Annual Meeting Abstracts 2011, 118:2825.
67. Pardanani A., Vannucchi A.M., Passamonti F., et al. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2011, 25:218-225.
68. Tefferi A. How I treat myelofibrosis. Blood 2011, 117:3494-3504.
69. Ugo V., Marzac C., Teyssandier I., et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004, 32:179-187.
70. Vannucchi A.M., Bogani C., Bartalucci N., et al. The mTOR inhibitor, RAD001, inhibits the growth of cells from patients with myeloproliferative neoplasms. ASH Annual Meeting Abstracts 2009, 114:2914.
71. Vannucchi A.M., Guglielmelli P., Gattoni E., et al. RAD001, an inhibitor of mTOR, shows clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (PPV/PET MF). ASH Annual Meeting Abstracts 2009, 114:307.
72. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
73. Guglielmelli P., Barosi G., Rambaldi A., et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood 2011, 118:2069-2076.
74. Fiskus W., Manepalli R.R., Balusu R., et al. Synergistic activity of combinations of JAK2 kinase inhibitor with PI3K/mTOR, MEK or PIM kinase inhibitor against human myeloproliferative neoplasm cells expressing JAK2V617F. ASH Annual Meeting Abstracts 2010, 116:798.
75. Khan I., Huang Z., Wen Q.J., et al. Inhibition of AKT signaling potently inhibits the growth of JAK and MPL-mutant cells in the myeloproliferative neoplasms in vitro and in vivo. ASH Annual Meeting Abstracts 2011, 118:3862.
76. Chung E., Kondo M. Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development. Immunol Res 2011, 49:248-268.
77. Odenike O., Curran E., Iyengar N., et al. Phase II study of the oral MEK inhibitor AZD6244 in advanced acute myeloid leukemia (AML). ASH Annual Meeting Abstracts 2009, 114:2081.
78. Bachmann M., Kosan C., Xing P.X., et al. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol 2006, 38:430-443.
79. Bachmann M., Moroy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 2005, 37:726-730.
80. Isaac M., Siu A., Jongstra J. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms. Drug Resist Updat 2011, 14:203-211.
81. Nawijn M.C., Alendar A., Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011, 11:23-34.
82. Zhang F., Beharry Z.M., Harris T.E., et al. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther 2009, 8:846-853.
83. Fiskus W.C., Buckley K.M., Rao R., et al. Synergistic activity of co-treatment with pim1 kinase inhibitor SGI-1776 and histone deacetylase inhibitor panobinostat or heat shock protein 90 inhibitor AUY922 against human CML and myeloproliferative neoplasm (MPN) cells. ASH Annual Meeting Abstracts 2009, 114. [abstract: 2651].
84. Keeton E., Palakurthi S., Alimzhanov M., et al. AZD1208, a novel, potent and selective pan PIM kinase inhibitor, demonstrates efficacy in models of acute myeloid leukemia. ASH Annual Meeting Abstracts 2011, 118. [abstract: 1540].
85. Wang J.C., Chen C., Dumlao T., et al. Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma 2008, 49:2321-2327.
86. Mithraprabhu S., Grigoriadis G., Khong T., et al. Deactylase inhibition in myeloproliferative neoplasms. Invest New Drugs 2010, 28(Suppl 1):S50-S57.
87. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6:38-51.
88. Arrowsmith C.H., Bountra C., Fish P.V., et al. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012, 11:384-400.
89. Glozak M.A., Sengupta N., Zhang X., et al. Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23.
90. Choudhary C., Kumar C., Gnad F., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
91. Sampath D., Liu C., Vasan K., et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012, 119:1162-1172.
92. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459-5468.
93. Dokmanovic M., Clarke C., Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007, 5:981-989.
94. Dickinson M., Johnstone R.W., Prince H.M. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 2010, 28:3-20.
95. Leoni F., Fossati G., Lewis E.C., et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005, 11:1-15.
96. Bali P., Pranpat M., Bradner J., et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005, 280:26729-26734.
97. Fiskus W., Pranpat M., Balasis M., et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 2006, 5:3096-3104.
98. Fiskus W., Pranpat M., Bali P., et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006, 108:645-652.
99. George P., Bali P., Annavarapu S., et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005, 105:1768-1776.
100. Wang Y., Fiskus W., Chong D.G., et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009, 114:5024-5033.
101. Fiskus W., Buckley K., Rao R., et al. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther 2009, 8:939-950.
102. DeAngelo D.J., Spencer A., Fischer T., et al. Activity of oral panobinostat (LBH589) in patients with myelofibrosis. ASH Annual Meeting Abstracts 2009, 114. [abstract: 2898].
103. Mascarenhas J., Mercado A., Rodriguez A., et al. Prolonged low dose therapy with a pan-deacetylase inhibitor, panobinostat (LBH589), in patients with myelofibrosis. ASH Annual Meeting Abstracts 2011, 118. [abstract: 794].
104. Baffert F., Evrot E., Ebel N., et al. Improved efficacy upon combined JAK1/2 and pan-deacetylase inhibition using ruxolitinib (INC424) and panobinostat (LBH589) in preclinical mouse models of JAK2V617F-driven disease. ASH Annual Meeting Abstracts 2011, 118:798.
105. Guerini V., Barbui V., Spinelli O., et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008, 22:740-747.
106. Rambaldi A., Dellacasa C.M., Finazzi G., et al. A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010, 150:446-455.
107. Rambaldi A., Finazzi G., Vannucchi A.M., et al. A phase II study of the HDAC inhibitor givinostat in combination with hydroxyurea in patients with polycythemia vera resistant to hydroxyurea monotherapy. ASH Annual Meeting Abstracts 2011, 118:1748.
108. Wang X., Zhang W., Tripodi J., et al. Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. Blood 2010, 116:5972-5982.
109. Shi J., Zhao Y., Ishii T., et al. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res 2007, 67:6417-6424.
110. Mascarenhas J., Hoffman R. Myeloproliferative neoplasms: new translational therapies. Mt Sinai J Med 2010, 77:667-683.
111. Creasy CL, McCabe MT, Korenchuk S, et al. A novel selective EZH2 inhibitor exhibits anti-tumor activity in lymphoma with EZH2 activating mutations. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 March 31-April 4. Chicago (IL), Philadelphia: AACR; 2012. Abstract 4700.
112. Picard D. Heat-shock protein 90, a chaperone for folding and regulation. Cell Mol Life Sci 2002, 59:1640-1648.
113. Trepel J., Mollapour M., Giaccone G., et al. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010, 10:537-549.
114. Taipale M., Jarosz D.F., Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010, 11:515-528.
115. Fiskus W., Verstovsek S., Manshouri T., et al. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin Cancer Res 2011, 17:7347-7358.
116. George P., Bali P., Cohen P., et al. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 2004, 64:3645-3652.
117. Pearl L.H., Prodromou C., Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008, 410:439-453.
118. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772.
119. Shay K.P., Wang Z., Xing P.X., et al. Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res 2005, 3:170-181.
120. Lancet J.E., Gojo I., Burton M., et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010, 24:699-705.
121. Samuel T.A., Sessa C., Britten C., et al. AUY922, a novel HSP90 inhibitor: final results of a first-in-human study in patients with advanced solid malignancies. J Clin Oncol 2010, 28(Suppl):15s. [abstract: 2528].
122. Proia D.A., Foley K.P., Korbut T., et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One 2011, 6:e18552.
123. Marubayashi S., Koppikar P., Taldone T., et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 2010, 120:3578-3593.
124. Weigert O., Lane A.A., Bird L., et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012, 209:259-273.
125. Lin T.L., Matsui W. Hedgehog pathway as a drug target: smoothened inhibitors in development. OncoTargets Ther 2012, 5:47-58.
126. Harris L.G., Samant R.S., Shevde L.A. Hedgehog signaling: networking to nurture a promalignant tumor microenvironment. Mol Cancer Res 2011, 9:1165-1174.
127. Irvine D.A., Copland M. Targeting hedgehog in hematologic malignancy. Blood 2012, 119:2196-2204.
128. Jamieson C., Cortes J.E., Oehler V., et al. Phase I dose-escalation study of PF-04449913, an oral Hedgehog (Hh) inhibitor, in patients with select hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 2011, 118. [abstract: 424].
129. Mosimann C., Hausmann G., Basler K. Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol 2009, 10:276-286.
130. Gehrke I., Gandhirajan R.K., Kreuzer K.A. Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and haematological cancers: multiplicity of therapeutic options. Eur J Cancer 2009, 45:2759-2767.
131. Curtin J.C., Lorenzi M.V. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010, 1:552-566.
132. Liu Y.C., Lai W.C., Chuang K.A., et al. Blockade of JAK2 activity suppressed accumulation of β-catenin in leukemic cells. J Cell Biochem 2010, 111:402-411.
133. Fiskus W., Smith J., Mudunuru U., et al. Treatment with β-catenin antagonist BC2059 exerts single agent efficacy and exerts improved activity with tyrosine kinase inhibitor (TKI) or pan-histone deacetylase (HDAC) inhibitor against human CML and myeloproliferative neoplasm (MPN) progenitor cells. Blood (ASH Annual Meeting Abstracts) 2011, 118. [abstract: 65].
134. McLornan D.P., Mead A.J., Jackson G., et al. Allogeneic stem cell transplantation for myelofibrosis in 2012. Br J Haematol 2012, 157:413-425.
135. Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2011, 86:1017-1026.
136. Ballen K.K., Shrestha S., Sobocinski K.A., et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010, 16:358-367.
137. Alchalby H., Badbaran A., Zabelina T., et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010, 116:3572-3581.